| A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward B Wang, O Van Oekelen, TH Mouhieddine, DM Del Valle, J Richter, ... Journal of hematology & oncology 13, 1-12, 2020 | 154 | 2020 |
| Bispecific antibodies in multiple myeloma: present and future G Lancman, DL Sastow, HJ Cho, S Jagannath, D Madduri, SS Parekh, ... Blood cancer discovery 2 (5), 423-433, 2021 | 90 | 2021 |
| Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy O Van Oekelen, K Nath, TH Mouhieddine, T Farzana, A Aleman, ... Blood 141 (7), 756-765, 2023 | 80 | 2023 |
| Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications S Bhalla, DT Melnekoff, A Aleman, V Leshchenko, P Restrepo, J Keats, ... Science Advances 7 (47), eabg9551, 2021 | 71 | 2021 |
| Selinexor in relapsed/refractory multiple myeloma J Richter, D Madduri, S Richard, A Chari Therapeutic advances in hematology 11, 2040620720930629, 2020 | 57 | 2020 |
| IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies G Lancman, K Parsa, K Kotlarz, L Avery, A Lurie, A Lieberman-Cribbin, ... Blood Cancer Discovery 4 (6), 440-451, 2023 | 49 | 2023 |
| Myeloma CAR-T CRS management with IL-1R antagonist anakinra SS Jatiani, A Aleman, D Madduri, A Chari, HJ Cho, S Richard, J Richter, ... Clinical Lymphoma Myeloma and Leukemia 20 (9), 632-636. e1, 2020 | 48 | 2020 |
| Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) Nex T chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in patients (pts … LJ Costa, SK Kumar, S Atrash, M Liedtke, G Kaur, BA Derman, ... Blood 140 (Supplement 1), 1360-1362, 2022 | 42 | 2022 |
| B-cell maturation antigen (BCMA) in multiple myeloma: The new frontier of targeted therapies L Sanchez, A Dardac, D Madduri, S Richard, J Richter Therapeutic Advances in Hematology 12, 2040620721989585, 2021 | 38 | 2021 |
| Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma TH Mouhieddine, O Van Oekelen, DT Melnekoff, J Li, Y Ghodke-Puranik, ... Blood advances 7 (6), 1056-1064, 2023 | 37 | 2023 |
| Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies G Lancman, K Parsa, C Rodriguez, J Richter, HJ Cho, S Parekh, ... Blood 140 (Supplement 1), 10073-10074, 2022 | 35 | 2022 |
| Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients A Aleman, O Van Oekelen, B Upadhyaya, K Beach, AK Zajdman, ... Cancer Cell 40 (5), 441-443, 2022 | 32 | 2022 |
| Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk S Richard, A Chari, S Delimpasi, M Simonova, I Spicka, L Pour, I Kriachok, ... American journal of hematology 96 (9), 1120-1130, 2021 | 32 | 2021 |
| An immunological syndrome featuring transverse myelitis, Evans syndrome and pulmonary infiltrates after unrelated bone marrow transplant in a patient with severe aplastic anemia S Richard, S Fruchtman, E Scigliano, D Skerrett, V Najfeld, L Isola Bone marrow transplantation 26 (11), 1225-1228, 2000 | 29 | 2000 |
| Stem cell transplantation and hematopoietic growth factors. S Richard, MW Schuster Current Hematology Reports 1 (2), 103-109, 2002 | 24 | 2002 |
| Comprehensive characterization of prolonged unexplained cytopenias in relapsed/refractory multiple myeloma patients following BCMA-directed CAR-T cell therapy S Thibaud, MB Mia, O Van Oekelen, TH Mouhieddine, C Schaniel, ... Blood 140 (Supplement 1), 614-616, 2022 | 22 | 2022 |
| Efficacy of intravenous immunoglobulin for preventing infections in patients with multiple myeloma G Lancman, K Lozada, N Athar, S Jacobs, J Doucette, HJ Cho, ... Clinical Lymphoma Myeloma and Leukemia 21 (5), e470-e476, 2021 | 19 | 2021 |
| A phase 1 study of CFT7455, a novel degrader of IKZF1/3, in multiple myeloma and non-Hodgkin lymphoma J Berdeja, S Ailawadhi, SM Horwitz, JV Matous, N Mehta-Shah, T Martin, ... Blood 138, 1675, 2021 | 17 | 2021 |
| A three-gene signature predicts response to selinexor in multiple myeloma P Restrepo, S Bhalla, Y Ghodke-Puranik, A Aleman, V Leshchenko, ... JCO Precision Oncology 6, e2200147, 2022 | 16 | 2022 |
| Effect of intravenous immunoglobulin on infections in multiple myeloma (MM) patients receiving daratumumab G Lancman, D Sastow, M Aslanova, E Moshier, HJ Cho, S Jagannath, ... Blood 136, 6-7, 2020 | 15 | 2020 |